(November 28, 2018) NEW YORK, NY – The Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Los Angeles Biomedical Research Institute, and University of Washington School of Medicine today announced the launch of the first clinical trial to test the safety and efficacy of a gel for men to prevent unintended pregnancy. Three trial sites in the U.S. are now enrolling couples.

NEW YORK, NEW YORK (November 14, 2018)  ̶  The Population Council has received initial funding from the Children’s Investment Fund Foundation (CIFF) to assess the feasibility of combining oral pre-exposure prophylaxis (PrEP) for HIV prevention with an oral contraceptive into a single pill, which women would take once a day.

October 24, 2018 -- Population Council researchers presented new evidence on promising biomedical and behavioral strategies to prevent HIV and other sexually transmitted infections at the HIV Research for Prevention (HIVR4P) conference in Madrid this week, the world’s only scientific meeting dedicated exclusively to biomedical HIV prevention.

September 24, 2018 – New research by the Population Council and partners shows that it may be possible to formulate a discreet, convenient, and woman-controlled multi-purpose technology to prevent HIV and other sexually transmitted infections (STIs) with limited risk of cross-resistance to antiretrovirals (ARV). This research published today in Nature Communications tests the non-antiretroviral agents, griffithsin (GRFT) and carrageenan (CG), in a fast-dissolving vaginal insert in rhesus macaques and mice.

The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. The approval marks an important step toward expanding contraceptive options for women.

Today the Population Council announced a new license agreement with TherapeuticsMD to make available the Council's investigational segesterone acetate/ ethinyl estradiol one-year vaginal system for contraception, to women in the United States. The agreement marks an important step toward expanding contraceptive options for women. 

Population Council researchers presented preclinical research results suggesting new strategies to prevent HIV and STIs from two studies at this week’s Conference on Retroviruses and Opportunistic Infections (CROI), the world’s preeminent HIV research meeting.  

The Population Council announces the appointment of Jonathan Shakes to the Board of Trustees. Mr. Shakes is an e-commerce logistics consultant, having worked fifteen years in operations, software and product management at Amazon and its subsidiaries.

The Population Council today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its one-year Nestorone® / ethinyl estradiol vaginal ring for pregnancy prevention. If approved, the contraceptive vaginal ring would be the first contraceptive option that provides a full year of protection against unintended pregnancy while fully under a woman’s control.